Immunovant (IMVT) Competitors

Krystal Biotech (NASDAQ:KRYS) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.

Which has stronger earnings & valuation, KRYS or IMVT?

Krystal Biotech has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$50.70M	88.56	$10.93M	$0.08	1,968.75
Immunovant	N/A	N/A	-$210.96M	-$1.84	-14.99

Does the MarketBeat Community believe in KRYS or IMVT?

Krystal Biotech received 167 more outperform votes than Immunovant when rated by MarketBeat users. However, 76.22% of users gave Immunovant an outperform vote while only 66.67% of users gave Krystal Biotech an outperform vote.

Company	Underperform	Outperform
Krystal Biotech	Outperform Votes 276 66.67%	Underperform Votes 138 33.33%
Immunovant	Outperform Votes 109 76.22%	Underperform Votes 34 23.78%

Does the media prefer KRYS or IMVT?

In the previous week, Krystal Biotech and Krystal Biotech both had 7 articles in the media. Immunovant's average media sentiment score of 0.67 beat Krystal Biotech's score of 0.21 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals have more ownership in KRYS or IMVT?

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by company insiders. Comparatively, 4.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, KRYS or IMVT?

Krystal Biotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Is KRYS or IMVT more profitable?

Immunovant's return on equity of -13.31% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	N/A	-13.31%	-12.61%
Immunovant	N/A	-57.97%	-52.47%

Do analysts recommend KRYS or IMVT?

Krystal Biotech presently has a consensus price target of $164.22, indicating a potential upside of 3.96%. Immunovant has a consensus price target of $48.00, indicating a potential upside of 72.66%. Given Krystal Biotech's higher possible upside, analysts clearly believe Immunovant is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunovant	0 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Krystal Biotech beats Immunovant on 11 of the 14 factors compared between the two stocks.